Objective: Advances in chemotherapy and chemoradiotherapy have enabled conversion of initially unresectable locally advanced (UR-LA) pancreatic adenocarcinoma (PDAC) to a resectable disease. However, definitive criteria for conversion surgery have not been established. We evaluated the potential of 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) to indicate conversion surgery in patients with primary UR-LA PDAC. Methods: Twenty consecutive patients with UR-LA PDAC underwent chemoradiation or chemotherapy followed by assessment with FDG-PET. We defined PET responders (standardized uptake value <3.0) with marked reduction (>80%) of carbohydrate antigen 19-9 as potential candidates for conversion surgery. Outcomes were compared with those of the patients with resectable (R; n = 94) and borderline resectable (BR; n = 37) PDAC.
Introduction
Pancreatic adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths worldwide and has the worst prognosis rate, with only 3% of patients surviving 5 years after diagnosis (1, 2) . Upon diagnosis,~15% of patients have resectable (R) disease (Stage I or II), 35% have locally advanced disease (Stage III), and 50% have metastatic disease (Stage IV) (3) . Although preoperative strategies to reduce the size and anatomical extent of carcinoma have been used in an attempt to downstage locally advanced PDAC, substantial downstaging of this disease is uncommon (4, 5) . We have reported cases of successful pancreatectomy with a high rate of negative pathological margins in patients with borderline resectable (BR) PDACs after neoadjuvant therapy (6) . Clinical decision-making processes have not been established for conversion surgery in patients with initially unresectable locally advanced (UR-LA) PDAC (7) .
Positron emission tomography (PET) uses positron-emitting radioisotopes attached to molecules that create different images, depending on tissue concentrations. Fluorodeoxyglucose (FDG)-PET/computed tomography (CT) has a high sensitivity and specificity, making it a valuable tool to diagnose and stage of cancer patients (8, 9) . Its reproducibility for quantitative metabolic measurements has been validated in malignant tumors including PDAC (10) (11) (12) (13) (14) (15) . In addition, a recent study confirmed that quantitative FDG-PET therapy assessment could predict survival outcomes of patients with UR-LA PDAC (16) . Because there is growing evidence that the standardized uptake value (SUV) is correlated to the aggressiveness of tumors, it is hypothesized that the SUV could predict complete resection (R0) for surgery. In this study, we evaluated the role of FDG-PET in patient selection for conversion surgery and surgical outcomes in patients with primary UR-LA PDAC.
Methods
Clinicopathological data were collected prospectively for all patients who received treatment for UR-LA PDAC between 2011 and 2016. Clinicopathological factors including age, sex, tumor location, tumor size, vascular involvement on CT, type of treatment, intraoperative blood loss, type of surgery, hospital length of stay, postoperative complications (Clavien-Dindo classification (17)), pathologic response (Evans classification (18) ) and postoperative chemotherapy were assessed. Changes in the carbohydrate antigen 19-9 (CA19-9) level, PET-SUV, and size of the maximum tumor on CT were evaluated. Unresectability was determined by two board certified pancreatic surgeons (Japanese Society of Hepato-Biliary-Pancreatic Surgery) and two radiologists based on the findings of multiple detector (MD)-CT, endosonography, and FDG-PET/CT, according to the National Comprehensive Cancer Network definitions (7) . These data were retrospectively analyzed. The Institutional Review Board of Kagawa University approved the study.
Initial treatment for UR-LA
Chemoradiation was offered primarily to patients with UR-LA PDAC between 2011 and 2014. The chemoradiation schedule consisted of external-beam radiotherapy (54 Gy in 27 fractions) with concurrent 5-fluorouracil 250 mg/m 2 /day given by continuous infusion or S-1 5 days/week. S-1 was administered orally at a dose of 60 mg/m 2 twice daily on the day of irradiation during radiation therapy. Three-dimensional treatment planning was completed with a CT simulator. Gross tumor volume (GTV) was determined with dynamic contrast-enhanced CT as the primary tumor volume, and the volume of the positive lymph nodes included the regional lymph nodes if they were ≥1 cm (lower axis) in diameter on any image. After completion of initial chemoradiation therapy, S-1 was administered at a dose of 80 mg/m 2 orally for 28 days, followed by a 14-day rest. Since 2015, for the first-line treatment of UR-LA PDAC, only chemotherapy consisting of FOLFIRINOX (leucovorin and fluorouracil plus irinotecan and oxaliplatin) has been considered. The regular FOLFIRINOX regimen (19) consisted of a 2-h intravenous infusion of oxaliplatin (85 mg/m 2 ) followed by a 2-h intravenous infusion of leucovorin (400 mg/m 2 ) concomitantly with a 90-min intravenous infusion of irinotecan (180 mg/m 2 ), followed by a bolus (400 mg/m 2 ) and a 46-h continuous infusion (2400 mg/m 2 ) of fluorouracil. The duration of one cycle was 2 weeks. All patients underwent dynamic MD-CT and FDG-PET/CT scans and an assessment of tumor markers every 3 or 4 months to follow the tumor response (Fig. 1 ). An institutional cancer board consisting of the attending surgeon, radiologist, and medical oncologist determined referrals for conversion surgery. Eligibility criteria for conversion surgery included radiological and clinical findings that would indicate complete resection (R0): no evidence of distant metastasis, FDG-PET negative (SUV < 3.0), and marked reduction (>80%) of CA19-9.
FDG-PET/CT imaging method (20)
Whole-body FDG-PET/CT examination was performed using a Biograph mCT64 PET/CT scanner (Siemens/CTI, Knoxville, TN, USA). The image systems enabled simultaneous acquisition of 74 transverse images per field of view (FOV), with an intersection spacing of 3 mm, for a total axial FOV of 21.6 cm. Prior to imaging, all patients fasted for 5 h before intravenous administration of FDG at a mean dose of 200 MBq (e.g., 3.7 MBq/kg weight). Whole-body PET/ CT images were acquired 120 min after administering FDG. Images were acquired with the patients resting in the supine position with their eyes closed. CT data were acquired first (tube rotation time 0.6 s per revolution, 120 kV, 192 mAs, reconstructed slice thickness of 3 mm) and used for attenuation correction and anatomical localization of the tumors. A region of interest was placed over each lesion to include the highest levels of radioactivity. The SUVmax was calculated with the following formula: SUV = cdc/(di/w), where cdc is the decaycorrected tracer tissue concentration (Bq/g), di is the injected dose (Bq), and w is the patient body weight (g).
MD-CT
The technical parameters used for the 64-slice MDCT (Aquilion 64, Toshiba Medical Systems, Tokyo, Japan) were as follows: a detector row configuration of 0.5 mm, pitch 53, reconstruction increment 0.4 mm, and section thickness 0.5 mm. Following the precontrast imaging, contrast material iopamidol (Iopamiron 300, Bayer Yakuhin, Osaka, Japan), was administered intravenously at a rate of 3-4 ml/s using an autonomic dual-head pump injector. The early-arterial, late-arterial, portal and delayed-phase scans were obtained at 25, 40, 70 and 180-s delays after aortic opacification had reached 100 HU.
Surgery
Briefly, pancreaticoduodenectomy was performed per the Whipple procedure, and the pancreatic remnant after pancreaticoduodenectomy was reconstructed with a pancreatojejunostomy. Distal pancreatectomy with celiac axis resection for pancreatic body cancer that involved the celiac axis, or the proximal part of the common hepatic artery was performedfor curative intent. When the portal vein or superior mesenteric vein was involved, portal vein/superior mesenteric vein resection was performed. Intraoperative pathological assessment of the pancreatic cut end margin was performed using frozen tissue sections. If the cut end margin was positive for adenocarcinoma, further resection of the pancreas was performed. Postoperative adjuvant chemotherapy was applied unless contraindicated by the patient's condition. The patients received gemcitabine or S-1 according to the recommended protocols, which were reported at the time of treatment (21, 22) . The pathological response in patients who underwent neoadjuvant chemoradiation was evaluated considering the residual tumor load according to the classification reported by Evans et al. (18, 23, 24) . The surgical margin in this study denoted either the stump of the pancreas, the bile duct, or the dissected plane around the pancreas (25) . If viable cancer cells were detected microscopically at the tip of any of these sites, the surgical margin was considered to be positive.
Comparison of R and BR PDAC
One-hundred and thirty-one consecutive patients with potential R (n = 94) or BR (n = 37) PDAC (26) , who received curative intent pancreatectomy between 2001 and 2016, were retrospectively analyzed to compare the clinical outcomes of primary UR-LA PDAC.
Statistical analysis
All statistical analyses were performed using the JMP software package (JMP 8.0 Inc., Cary, NC, USA). Patient demographics, FDG-PET SUV, CA19-9 level, perioperative results, and pathological results were compared using the Mann-Whitney U test for continuous variables and Fisher's exact test or the chi-square test for categorical variables. Data of 3 or 4 groups were analyzed by using one-way analysis of variance. Throughout this study, P values <0.05 (two-sided) were considered statistically significant. Survival was calculated from the start of initial treatment. Overall survival (OS) was estimated with the Kaplan-Meier method, and the differences in survival in the univariate analysis were assessed with the log-rank test.
Results

Conversion surgery for initially UR-LA PDAC
Twenty patients with primary UR-LA PDAC underwent primary chemoradiation (n = 15) or chemotherapy (n = 5) according to institutional protocols. The Institutional GI Cancer Board reevaluated the patients' resectability every 3 or 4 months during subsequent chemotherapy. Eight of the 20 patients (40%) were considered candidates for conversion surgery based on a PET negative result (SUV < 3.0), no evidence of distant metastasis, and a marked reduction in CA19-9 over a period of 3-9 months (median, 5 months) after the initiation of therapy (UR-LAR). The individual patients' clinical background, perioperative Table 1 ) treated with 54 Gy of radiation and concurrent 5-fluorouracil followed by S1. Multiple detector-CT revealed that the tumor involved the celiac artery (A) and superior mesenteric artery. The tumor size and anatomic relationship with the celiac artery did not change at the time of consideration for conversion surgery (B). The SUV (3.99) of FDG-PET (C) had decreased to 2.85 upon consideration for conversion surgery (D). The patient was free of disease for 66 months since the initial treatment (61 months after conversion surgery). Abbreviations: CT, computed tomography; FDG-PET, 18 F-fluorodeoxyglucose positron emission tomography; SUV, standardized uptake value; UR-LA, unresectable locally advanced.
data, and outcomes are illustrated in Table 1 . MD-CT revealed that six patients (75%) had stable disease, and two patients (75%) had a partial response to therapy. Pre-treatment CA19-9 was elevated (>37 U/mL) in 6 of 8 patients. Among these six patients, the rate of reduction in CA19-9 levels from pre-treatment to pre-operation was 77-99% (median, 90%). Pancreaticoduodenectomy was performed in four patients combined with portal vein (n = 4) and common hepatic artery (n = 1) resections. Distal pancreatectomy with celiac axis resection was performed in four patients combined with portal vein (n = 1) resections. R0 resection was confirmed in 7 of 8 patients (87.5%) by pathological evaluation. The CT and PET images of a representative case (Case 1) are shown in Fig. 1 . The histopathological findings are shown in the Supplemental material. The patients received gemcitabine (n = 3) or S-1 (n = 5) as postoperative adjuvant chemotherapy per the recommended protocols. Two patients (Nos. 4 and 5 in Table 1 ) developed recurrence of lung metastasis or para-aortic lymph node metastasis during the follow-up (10-66 months; median, 30 months). Two patients (Nos. 2 and 7 in Table 1 ) died of aspiration pneumonia without obvious recurrence (50 and 15 months after diagnosis). One patient (No. 5 in Table 1 ) died from lung metastasis and carcinomatous pleurisy (21 months after diagnosis).
FDG-PET and CA19-9 levels prior to consideration for surgery in UR-LA, R, and BR PDAC There were no significant differences in the background characteristics among the patients with primary UR-LA, R, or BR PDAC ( Table 2 ). All 20 patients with UR-LA had a pre-treatment PET scan; median SUV was 6.98 (range, 2.46-14.86). The median SUV decreased to 2.27 (range, 1.71-2.85) in patients who underwent conversion surgery, and 3.1 (range, 2.68-11.22) in patients who did not receive surgery (P = 0.063). The median pre-treatment SUV was significantly lower in patients who underwent conversion surgery compared to that in patients who did not have surgery (P = 0.038).
The median SUV reduction rates were 44% (range, 29-78%) in patients who underwent conversion surgery and 50% (range, −9% to 76%) in patients who did not undergo surgery (P = 0.32). The median SUV at the time of consideration for surgery was significantly lower in the UR-LAR patients who underwent conversion surgery compared to that in patients with R (P = 0.015) or BR (P = 0.002) PDAC who did not receive neoadjuvant treatment. The CA19-9 levels decreased significantly both in the patients with UR-LAR who underwent conversion surgery and in those who did not undergo surgery (P < 0.001) during the treatment. The reduction rates were 95.6% in the patients with UR-LAR who underwent conversion surgery and 87.9% in those who did not receive surgery. There were no significant differences in the preoperative CA19-9 levels among the patients with primary UR-LA, R or BR PDAC.
Perioperative and pathological outcomes
Perioperative and pathological outcomes in patients with UR-LAR, R, and BR PDAC are illustrated in Table 3 . There were significant differences in intraoperative blood loss (P = 0.0065) and operative time (P < 0.0001) among the groups. The operative time was significantly longer in the UR-LAR group than in the R group (P < 0.05). There was no significant difference in morbidity, mortality or length of hospital stay among the groups.
Pathologically negative margins were achieved in 7 of 8 patients (87.5%) in the UR-LAR group, 89 of 94 patients (94.7%) in the R group, and 31 of 37 patients (83.8%) in the BR group (P = 0.14) who underwent pancreatectomy. There was no significant difference in R0 rates among the groups. There were significant differences in positive lymph nodes (P = 0.05), portal vein invasion (P < 0.0001), arterial invasion (P = 0.03), lymphatic invasion (P = 0.02), extrapancreatic nerve plexus invasion (P = 0.0002), serosal invasion (P = 0.03), and main pancreatic duct invasion (P = 0.008) among the groups. The frequencies of positive lymph node, lymphatic invasion, serosal invasion, and main pancreatic duct invasion were significantly lower (P < 0.05) in the UR-LAR group than in the BR group.
Overall survival
The overall survival curve determined using the Kaplan-Meier method with the log-rank test is illustrated in Fig. 2 . The median follow-up period was 30 months (10-65 months). The OS curve was better in the UR-LAR group than in the UR-LA group who did not receive surgery.
There was no significant difference in the OS curve between the UR-LAR group and the R group (P = 0.45) or BR group (P = 0.4).
Discussion
FDG-PET is a functional imaging method that is specific to metabolically active cancer cells. Recent studies support the application of PET in the assessment of cancer treatment in esophageal, breast, and head and neck cancers (27) . Several studies have evaluated the usefulness of PET in patients with PDAC who received treatment (11, 12, 28) . Bang et al. (13) reported a response evaluation using CT and PET in patients with PDAC who received concurrent chemoradiation. Patients who had marked reduction in SUV (>50%) had longer times to tumor progression. Choi et al. (29) reported that all patients who had marked reduction in SUV (>50%) underwent complete surgical resection (R0) as compared to only 6% of non-responders. The present study proposed PET responders (SUV < 3.0) with marked reduction (>80%) of CA19-9 to be potential candidates for conversion surgery. The rationale of this cutoff value setting was based on a previous study of FDG-PET for patients with head and neck cancer who underwent chemoradiation in our institution (30) . In this study, a post-treatment SUV of 3.0 as the cut-off value provided the best positive predictive value for therapeutic response. Gourin et al. (31) also recommended an SUV cutoff value of 3.0 to predict R0 resection. An SUV of 3.5 on FDG-PET was used for differentiating between malignant and benign pancreatic tumors in our institution (32) . We also reported the role of FDG-PET in the surgical management of patients with R/BR pancreatic cancer (33) . There was a statistically significant difference (P = 0.02) in the SUV between patients with resectable (4.6 ± 2.9) and unresectable (7.8 ± 4.5) pancreatic cancer. To achieve an acceptable rate of R0 resection in the conversion surgery, we used a strict cutoff value of SUVmax < 3.0 to determine candidates for conversion surgery. In the present study, 7 of 8 patients (87.5%) who had negative SUV (<3.0) at the consideration for conversion surgery achieved complete surgical resection (R0) and had an encouraging prognosis.
A limitation of PET is that 5-10% of pancreatic carcinomas are not detectable by FDG PET (9) . Preoperative CA19-9 levels correlate with postoperative survival, and postoperative levels predict survival duration. Several authors already have documented a significant association between preoperative CA19-9 values and the identification of sub-radiographic, unresectable pancreatic cancer with systemic metastases (34) (35) (36) (37) (38) (39) . The CA19-9 response to neoadjuvant therapy has been reported as another potential marker for the R0 resection rate, histopathologic response, and survival. Boone et al. reported a pathologically complete response in 5 (6%) of 78 patients with resectable, BR, or LA-PDAC, and these patients all had a >90% decrease in CA19-9 (10). Patel et al. reported the usefulness of the CA 19-9 reduction rate (>85%) and PET scans for R0 resections in patients with borderline resectable pancreatic cancer who received neoadjuvant induction chemotherapy followed by 5-FU-IMRT (14) . Based on these reports, we defined the cutoff value of >80% reduction in the serum CA19-9 level as a complementary factor of SUV for conversion surgery. A weakness of this method is the inability to assess changes in patients with low CA19-9 levels and patients with Lewis a-b-blood type who do not secrete CA19-9 (40). Pre-treatment CA19-9 levels were low in 2 of 8 (25%) patients in this study, similar to a previous report (40) . Our perception of the combination criteria is that FDG PET and CA19-9 could play complementary roles to combat each of their weaknesses of a falsenegative estimation in selecting candidates for conversion surgery during neoadjuvant therapy. Furthermore, the combined assessment of CA19-9 and FDG-PET could play complementary roles in monitoring radiographically occult systemic disease and locally viable disease, which are associated with pathologically positive margins. RECIST, based on conventional radiologic assessment, is a wellaccepted criterion for treatment response in various solid cancers. However, only 2 of 8 patients (25%) with UR-LAR showed a partial response (RECIST) upon consideration for conversion surgery. The other six patients with stable disease (75%) had R0 resection and achieved a noticeable pathological response to neoadjuvant treatment. Katz et al. (41) also reported that radiographic measures of treatment response in patients with BR PDAC appear to be of little clinical value. Current radiographic imaging, including MD-CT, cannot distinguish between fibrosis and viable cancer, which is the basis for the structural relationship between the tumor and arteries that indicates unresectability on imaging. Our study suggests that PET responders should be considered as candidates for conversion surgery for UR-LA PDAC.
The present study suggested the feasibility and safety of conversion surgery in patients with primary UR-LA PDAC compared to those with R and BR PDAC. Although the conversion surgery for UR-LA PDAC was frequently combined with complicated vascular resection, the morbidity and mortality rates were similar to those of the R and BR groups. A significant infrequency in lymphovascular invasion and lymph node positivity was identified in patients with UR-LA who underwent conversion surgery compared to that in patients with BR. Improvements in node positivity, lymphovascular invasion, perineural invasion and R0 resection in conversion surgery should contribute to improved survival.
The current study has several limitations. First, the treatment regimens that the patients received were not identical and included chemoradiation and chemotherapy. A second limitation is the small number of patients with primary UR-LA PDAC who received precise assessment for conversion surgery. Therefore, it remains unclear whether surgical intervention is contraindicated for patients with UR-LA PDAC who did not meet our criteria for conversion surgery. Although our study was limited by a small sample size, this is the first study to confirm encouraging survival data using valid methods, including FDG-PET and CA19-9 assessment for conversion surgery in patients with primary UR-LA PDAC. Studies with a larger sample size are needed to determine whether an SUV proportional change or a numerical cutoff can be used for conversion surgery in patients with PDAC.
Conclusions
The combined assessment of FDG-PET and CA19-9 could be a potential indicator for conversion surgery in patients with primary UR-LA PDAC and may be used to aid in selecting patients who could undergo complete surgical resection and have an encouraging prognosis. Figure 2 . Overall survival curve. The overall survival curve was better in the UR-LAR group than in the UR-LA group who did not receive surgery. There was no significant difference in overall survival between the UR-LAR group and the R group (P = 0.45) or BR group (P = 0.4). Abbreviations: BR, borderline resectable; R, resectable; UR-LA, unresectable locally advanced; UL-LAR group, patients with primary UR-LA pancreatic adenocarcinoma who underwent conversion surgery.
